Kiromic BioPharma (KRBP) Competitors $0.92 +0.00 (+0.01%) (As of 12/20/2024 04:04 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends KRBP vs. SYRS, GTBP, HOTH, IMCC, CANF, ELAB, BMRA, PPBT, AEZS, and UPXIShould you be buying Kiromic BioPharma stock or one of its competitors? The main competitors of Kiromic BioPharma include Syros Pharmaceuticals (SYRS), GT Biopharma (GTBP), Hoth Therapeutics (HOTH), IM Cannabis (IMCC), Can-Fite BioPharma (CANF), Elevai Labs (ELAB), Biomerica (BMRA), Purple Biotech (PPBT), Aeterna Zentaris (AEZS), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry. Kiromic BioPharma vs. Syros Pharmaceuticals GT Biopharma Hoth Therapeutics IM Cannabis Can-Fite BioPharma Elevai Labs Biomerica Purple Biotech Aeterna Zentaris Upexi Kiromic BioPharma (NASDAQ:KRBP) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations, institutional ownership and risk. Does the MarketBeat Community believe in KRBP or SYRS? Syros Pharmaceuticals received 366 more outperform votes than Kiromic BioPharma when rated by MarketBeat users. Likewise, 63.06% of users gave Syros Pharmaceuticals an outperform vote while only 50.00% of users gave Kiromic BioPharma an outperform vote. CompanyUnderperformOutperformKiromic BioPharmaOutperform Votes150.00% Underperform Votes150.00% Syros PharmaceuticalsOutperform Votes36763.06% Underperform Votes21536.94% Does the media prefer KRBP or SYRS? In the previous week, Kiromic BioPharma's average media sentiment score of 0.00 beat Syros Pharmaceuticals' score of -0.71 indicating that Kiromic BioPharma is being referred to more favorably in the media. Company Overall Sentiment Kiromic BioPharma Neutral Syros Pharmaceuticals Negative Which has more volatility and risk, KRBP or SYRS? Kiromic BioPharma has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Do analysts recommend KRBP or SYRS? Syros Pharmaceuticals has a consensus price target of $3.33, indicating a potential upside of 1,566.67%. Given Syros Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Syros Pharmaceuticals is more favorable than Kiromic BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiromic BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Is KRBP or SYRS more profitable? Kiromic BioPharma's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kiromic BioPharmaN/A N/A -241.14% Syros Pharmaceuticals N/A -3,369.56%-97.04% Which has better valuation & earnings, KRBP or SYRS? Kiromic BioPharma has higher earnings, but lower revenue than Syros Pharmaceuticals. Kiromic BioPharma is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiromic BioPharmaN/AN/A-$20.95M-$6.55-0.14Syros Pharmaceuticals$386K13.90-$164.57M-$3.03-0.07 Do insiders and institutionals have more ownership in KRBP or SYRS? 10.9% of Kiromic BioPharma shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 20.6% of Kiromic BioPharma shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummarySyros Pharmaceuticals beats Kiromic BioPharma on 10 of the 15 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Kiromic BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for KRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRBP vs. The Competition Export to ExcelMetricKiromic BioPharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.41M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-0.1446.7390.1317.19Price / SalesN/A415.011,116.25117.05Price / CashN/A182.1043.1037.85Price / Book-0.133.894.784.78Net Income-$20.95M-$42.21M$120.31M$225.60M7 Day Performance-3.15%-2.15%-1.92%-1.23%1 Month Performance-15.59%1.73%13.65%0.46%1 Year Performance220.03%16.36%28.34%15.24% Kiromic BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRBPKiromic BioPharmaN/A$0.92+0.0%N/A+162.9%$1.41MN/A-0.1435Gap UpHigh Trading VolumeSYRSSyros Pharmaceuticals4.2521 of 5 stars$0.21+2.9%$3.33+1,463.5%-96.5%$5.72M$9.94M-0.07120Gap UpGTBPGT Biopharma3.6544 of 5 stars$2.51-8.7%$11.00+338.2%-78.3%$5.61MN/A0.008Positive NewsGap UpHOTHHoth Therapeutics2.0095 of 5 stars$0.81+0.1%$3.50+331.6%-30.8%$5.60MN/A-0.614Gap UpIMCCIM Cannabis0.0474 of 5 stars$2.38-3.6%N/A+3.4%$5.31M$51.39M-0.72340Gap DownCANFCan-Fite BioPharma1.7922 of 5 stars$1.50-5.1%$14.00+833.4%-30.7%$5.31M$667,000.00-0.888ELABElevai Labs0.3441 of 5 stars$2.04-10.9%N/A-99.3%$5.28M$2.45M-0.0318News CoverageGap DownBMRABiomerica0.1423 of 5 stars$0.31-0.7%N/A-76.8%$5.24M$5.51M-0.8260Gap DownPPBTPurple Biotech1.6642 of 5 stars$3.93+2.6%$33.00+739.7%N/A$5.23MN/A-0.4720AEZSAeterna ZentarisN/A$2.90flatN/A-68.1%$5.20M$2.37M-0.2020Analyst ForecastUPXIUpexi2.3417 of 5 stars$4.84-1.2%$25.00+416.5%-79.2%$5.05M$83.98M0.00130Earnings ReportPositive NewsGap Down Related Companies and Tools Related Companies SYRS Competitors GTBP Competitors HOTH Competitors IMCC Competitors CANF Competitors ELAB Competitors BMRA Competitors PPBT Competitors AEZS Competitors UPXI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KRBP) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiromic BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiromic BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
